Shares of Stryker Co. (NYSE:SYK) have been given a consensus rating of “Buy” by the twenty-three ratings firms that are currently covering the company, Marketbeat reports. Seven research analysts have rated the stock with a hold recommendation and sixteen have issued a buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $181.15.
Several research firms have weighed in on SYK. Zacks Investment Research raised Stryker from a “hold” rating to a “buy” rating and set a $180.00 price target on the stock in a report on Tuesday. Oppenheimer set a $170.00 price target on Stryker and gave the company a “hold” rating in a report on Friday, October 26th. Barclays began coverage on Stryker in a report on Monday, October 15th. They issued an “overweight” rating and a $198.00 price target on the stock. JPMorgan Chase & Co. raised their price target on Stryker to $200.00 and gave the company an “overweight” rating in a report on Thursday, September 13th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $187.00 price target on shares of Stryker in a report on Wednesday, September 12th.
In related news, VP Katherine Ann Owen sold 37,866 shares of the firm’s stock in a transaction dated Wednesday, September 5th. The stock was sold at an average price of $166.84, for a total transaction of $6,317,563.44. Following the transaction, the vice president now directly owns 11,367 shares of the company’s stock, valued at approximately $1,896,470.28. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Glenn S. Boehnlein sold 750 shares of the firm’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $178.17, for a total value of $133,627.50. Following the transaction, the chief financial officer now directly owns 2,785 shares in the company, valued at $496,203.45. The disclosure for this sale can be found here. Company insiders own 7.40% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. MayTech Global Investments LLC grew its position in Stryker by 9.5% during the 2nd quarter. MayTech Global Investments LLC now owns 18,487 shares of the medical technology company’s stock worth $3,122,000 after acquiring an additional 1,604 shares during the last quarter. Chartwell Investment Partners LLC bought a new position in Stryker during the 2nd quarter worth approximately $1,409,000. Nissay Asset Management Corp Japan ADV grew its position in Stryker by 1.4% during the 2nd quarter. Nissay Asset Management Corp Japan ADV now owns 40,024 shares of the medical technology company’s stock worth $6,758,000 after acquiring an additional 544 shares during the last quarter. Atlantic Trust LLC bought a new position in Stryker during the 2nd quarter worth approximately $105,000. Finally, Moneta Group Investment Advisors LLC grew its position in Stryker by 354,407.4% during the 2nd quarter. Moneta Group Investment Advisors LLC now owns 95,717 shares of the medical technology company’s stock worth $135,000 after acquiring an additional 95,690 shares during the last quarter. 75.21% of the stock is currently owned by institutional investors.
Shares of NYSE:SYK traded up $4.35 on Thursday, hitting $166.57. The company’s stock had a trading volume of 1,741,579 shares, compared to its average volume of 1,330,247. Stryker has a 1 year low of $146.80 and a 1 year high of $179.84. The stock has a market cap of $60.63 billion, a P/E ratio of 25.67, a PEG ratio of 2.23 and a beta of 0.59. The company has a quick ratio of 1.21, a current ratio of 1.91 and a debt-to-equity ratio of 0.60.
Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, October 25th. The medical technology company reported $1.69 earnings per share for the quarter, beating the consensus estimate of $1.68 by $0.01. Stryker had a return on equity of 28.00% and a net margin of 9.31%. The firm had revenue of $3.24 billion for the quarter, compared to analysts’ expectations of $3.26 billion. On average, equities research analysts expect that Stryker will post 7.28 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, October 31st. Investors of record on Friday, September 28th were issued a dividend of $0.47 per share. The ex-dividend date of this dividend was Thursday, September 27th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 1.13%. Stryker’s dividend payout ratio is 28.97%.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Read More: Risk Tolerance
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.